Skip to main
NEO

NeoGenomics (NEO) Stock Forecast & Price Target

NeoGenomics (NEO) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NeoGenomics is poised for strong growth, with its 85% clinical services division utilizing its state-of-the-art laboratories and broad test menu to cater to the rapidly growing demand for oncology diagnostic testing. While the company faces challenges in integrating acquired businesses and navigating complex regulatory environments, it has strong potential for growth in its competitive landscape. Additionally, its recent financial results have been in line with expectations and its optimistic outlook for the future, including continued double-digit growth and potential margin expansion, makes it an attractive investment opportunity.

Bears say

NeoGenomics is facing unpredictability in public and private reimbursement, as well as pressure to remain competitive against sophisticated lab competitors, leading to potential lower margins as competitors gain share of the market. The company's recent launch of the RaDaR ST MRD test and plans to expand its indications in the second half of 2026 may drive revenue growth, but this could be offset by increased expenses from sales force expansion and integration of acquisitions. The company's financial results for the second quarter of 2026 will be a key indication of its ability to execute on its plans and maintain competitive positioning in the market.

NeoGenomics (NEO) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NeoGenomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NeoGenomics (NEO) Forecast

Analysts have given NeoGenomics (NEO) a Buy based on their latest research and market trends.

According to 6 analysts, NeoGenomics (NEO) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $16.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $16.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NeoGenomics (NEO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.